1. prisoner 2. pregnancy 3. breast feeding 4. symptoms of acute respiratory infection for \>10 days before randomization 5. \>48 hours between meeting inclusion criteria and randomization 6. seizure disorder 7. porphyria cutanea tarda 8. diagnosis of long qt syndrome 9. qtc \>500 ms on electrocardiogram within 72 hours prior to enrollment 10. known allergy to hydroxychloroquine, chloroquine, or amodiaquine 11. receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol 12. receipt of \>1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment 13. inability to receive enteral medications 14. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 15. previous enrollment in this trial 16. the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient

1. prisoner 2. pregnancy 3. breast feeding 4. symptoms of acute respiratory infection for \>10 days before randomization 5. \>48 hours between meeting inclusion criteria and randomization 6. seizure disorder 7. porphyria cutanea tarda 8. diagnosis of long qt syndrome 9. qtc \>500 ms on electrocardiogram within 72 hours prior to enrollment 10. known allergy to hydroxychloroquine, chloroquine, or amodiaquine 11. receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol 12. receipt of \>1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment 13. inability to receive enteral medications 14. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 15. previous enrollment in this trial 16. the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient

prisoner pregnancy breast feeding symptoms of acute respiratory infection for >10 days before randomization >48 hours between meeting inclusion criteria and randomization seizure disorder porphyria cutanea tarda diagnosis of long qt syndrome qtc >500 ms on electrocardiogram within 72 hours prior to enrollment known allergy to hydroxychloroquine, chloroquine, or amodiaquine receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment inability to receive enteral medications refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 previous enrollment in this trial the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient

prisoner pregnancy breast feeding symptoms of acute respiratory infection for >10 days before randomization >48 hours between meeting inclusion criteria and randomization seizure disorder porphyria cutanea tarda diagnosis of long qt syndrome qtc >500 ms on electrocardiogram within 72 hours prior to enrollment known allergy to hydroxychloroquine, chloroquine, or amodiaquine receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment inability to receive enteral medications refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 previous enrollment in this trial the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient

1. prisoner 2. pregnancy 3. breast feeding 4. symptoms of acute respiratory infection for >10 days before randomization 5. >48 hours between meeting inclusion criteria and randomization 6. seizure disorder 7. porphyria cutanea tarda 8. diagnosis of long qt syndrome 9. qtc >500 ms on electrocardiogram within 72 hours prior to enrollment 10. known allergy to hydroxychloroquine, chloroquine, or amodiaquine 11. receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol 12. receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment 13. inability to receive enteral medications 14. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 15. previous enrollment in this trial 16. the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient

1. prisoner 2. pregnancy 3. breast feeding 4. symptoms of acute respiratory infection for >10 days before randomization 5. >48 hours between meeting inclusion criteria and randomization 6. seizure disorder 7. porphyria cutanea tarda 8. diagnosis of long qt syndrome 9. qtc >500 ms on electrocardiogram within 72 hours prior to enrollment 10. known allergy to hydroxychloroquine, chloroquine, or amodiaquine 11. receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol 12. receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment 13. inability to receive enteral medications 14. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 15. previous enrollment in this trial 16. the treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient